Nuvectis Pharma announces U.S. FDA granted ODD for NXP800
PremiumThe FlyNuvectis Pharma announces U.S. FDA granted ODD for NXP800
3M ago
Nuvectis Pharma cancer treatment granted FDA orphan designation
Premium
The Fly
Nuvectis Pharma cancer treatment granted FDA orphan designation
3M ago
Nuvectis Pharma reports Q2 net loss $4.4M vs. $5.8M last year
Premium
The Fly
Nuvectis Pharma reports Q2 net loss $4.4M vs. $5.8M last year
3M ago
Nuvectis Pharma Inc trading halted, volatility trading pause
PremiumThe FlyNuvectis Pharma Inc trading halted, volatility trading pause
8M ago
Nuvectis Pharma announces preliminary data from NXP800 Phase 1b trial
Premium
The Fly
Nuvectis Pharma announces preliminary data from NXP800 Phase 1b trial
8M ago
Nuvectis Pharma reports FY23 EPS ($1.43) vs ($1.51) last year
Premium
The Fly
Nuvectis Pharma reports FY23 EPS ($1.43) vs ($1.51) last year
8M ago
Nuvectis Pharma announces ODD granted by FDA to NXP800
PremiumThe FlyNuvectis Pharma announces ODD granted by FDA to NXP800
1y ago
Nuvectis granted orphan status for cholangiocarcinoma treatment
Premium
The Fly
Nuvectis granted orphan status for cholangiocarcinoma treatment
1y ago
Nuvectis Pharma reports Q2 EPS (38c), consensus (29c)
Premium
The Fly
Nuvectis Pharma reports Q2 EPS (38c), consensus (29c)
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100